All News

Mobile health interventions have the potential to help people living with HIV improve engagement in care, promote medication adherence, and in turn, improve patient outcomes.

A personalized medicine knowledge gap currently exists between many healthcare providers in the United States, and around the globe.

Nivolumab (Opdivo) plus ipilimumab (Yervoy) approved for patients with microsatellite instability high or mismatch repair deficient metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.

Research to explore whether intermittent fasting can improve symptoms in patients with relapsing-remitting multiple sclerosis.

Point-of-care testing can help patients determine whether or not they need to see a prescriber for an antibiotic or for other types of treatment, and it can address the growing primary care provider shortage.

Olaparib (Lynparza, Merck and AstraZeneca) demonstrated significant improvement in progression-free survival in the first-line maintenance setting for women with advanced BRCA-mutated ovarian cancer.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

An experimental HIV-1 vaccine regimen was well-tolerated and produced immune responses against HIV in humans and rhesus monkeys.

Hepatocellular carcinoma is the most common type of liver cancer in adults.

Approvals and indications of this drug were based on 3 main clinical trials.

Some pharmacy schools now use Pharmacy Curriculum Outcomes Assessment scores for academic probation.

Newly revised standards support quality education, and training for the technician workforce, according to the organizations.

Officials with the FDA are requiring safety label updates for fluoroquinolone antibiotics due to risks of mental health adverse effects, and blood sugar disturbances.

Even as fewer patients are using them, the 10 medications with the highest spend in Medicare Part D have seen substantial increases in spending and out-of-pocket costs.

Officials with the FDA are requiring safety label updates for fluoroquinolone antibiotics due to risks of mental health adverse effects and blood sugar disturbances, according to a press release

Results from a phase 3 study and post-hoc analysis highlight the use of galcanezumab-gnlm (Emgality, Eli Lilly) for the treatment of episodic cluster headache and migraine.

The FDA has granted an accelerated approval to the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the treatment of eligible patients aged 12 years and older with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer (mCRC).

The updated labeling will strengthen warnings for mental health adverse effects and risks related to hypoglycemia.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

New research identified predictors of long-term survival and health-related quality of life in patients with newly diagnosed multiple myeloma.

Information regarding the opioid crisis, lofexidine hydrochloride versus clonidine, and clinical pearls that pharmacists should know about.

A recent systematic review has shed light on increased glucose intake in the modern diet and the effects on mechanisms in the body.

The US Food and Drug Administration (FDA) has granted the US Department of Defense (DoD) an emergency use authorization (EUA) of freeze-dried plasma product (FDP) that is made in France.

Patients on atypical antipsychotics have 3 to 5 times greater risk of type 2 diabetes than others.

Two commonly used agents for the treatment of diarrhea are now being abused to obtain opioid-like highs.

Coffee drinkers with genetic polymorphisms may not need to be concerned with their coffee consumption based on new research.

Pharmaceutical manufacturers depend on hubs to act as connectors between various stakeholders across the specialty drug prescribing process.

In the phase 3 PALOMA-3 trial, Pfizer’s palbociclib (Ibrance) narrowly missed reaching its secondary endpoint of overall survival (OS), according to a press release.